MaaT Phar­ma and CD­MO Skyephar­ma un­veil be­spoke, and po­ten­tial­ly largest, mi­cro­bio­me fa­cil­i­ty in Eu­rope

MaaT Phar­ma and CD­MO Skyephar­ma have just com­plet­ed build­ing what might be the largest cGMP mi­cro­bio­me fa­cil­i­ty in Eu­rope. Com­plet­ed in 12 months, the 17,200-square-foot fa­cil­i­ty in France was de­signed from scratch to specif­i­cal­ly house the man­u­fac­tur­ing of MaaT’s mi­cro­bio­me can­cer ther­a­pies.

Ly­on, France-based MaaT har­vests stool sam­ples from healthy donors, which are mixed to­geth­er to form a sus­pen­sion and ad­min­is­tered to pa­tients. The biotech has three can­cer as­sets un­der in­ves­ti­ga­tion based on its ap­proach.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER